Related Articles
Low‑dose anlotinib combined with EGFR‑TKI can be used as an alternative for EGFR‑TKI‑resistant non‑small cell lung cancer in elderly patients
Utidelone combined with anti‑angiogenic therapy for the treatment of anthracycline/taxane‑treated and endocrine‑resistant HR<sup>+/</sup>HER2<sup>‑</sup> refractory breast cancer with brain metastases: A case report
PALB2 upregulation is associated with a poor prognosis in pancreatic ductal adenocarcinoma
Metastatic breast cancer with double heterozygosity for the <em>BRCA1 </em>and <em>BRCA2</em> genes responding to olaparib: A case report
Toripalimab combined with anlotinib for recurrent extensive‑stage small‑cell lung cancer: A case report